5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
    31.
    发明授权
    5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones 失效
    5,8-二氢-6H-吡啶并[2,3-d]嘧啶-7-酮

    公开(公告)号:US07098332B2

    公开(公告)日:2006-08-29

    申请号:US10731594

    申请日:2003-12-08

    IPC分类号: C07D471/04 A61K31/519

    CPC分类号: C07D471/04

    摘要: The invention provides 5,8-dihydro-6H-pyrido[2,3-d]pyrimidin-7-one compounds that are selective inhibitors of KDR and FGFR kinases, and are useful in the treatment of cancers. The compounds have the generic structure I where Ar, Ar′, and R1 are as set forth in the present specification. The invention also provides pharmaceutical compositions containing these compounds and methods for their use.

    摘要翻译: 本发明提供作为KDR和FGFR激酶的选择性抑制剂的5,8-二氢-6H-吡啶并[2,3-d]嘧啶-7-酮化合物,并且可用于治疗癌症。 化合物具有通式结构I,其中Ar,Ar'和R 1如本说明书所述。 本发明还提供含有这些化合物的药物组合物及其使用方法。

    4,5-pyrazinoxindoles
    32.
    发明授权
    4,5-pyrazinoxindoles 失效
    4,5 - 吡嗪并吲哚

    公开(公告)号:US06221867B1

    公开(公告)日:2001-04-24

    申请号:US09464534

    申请日:1999-12-15

    IPC分类号: C07D24136

    CPC分类号: C07D487/04

    摘要: Disclosed are novel 4,5-pyrazinoxindoles having the formula These compounds inhibit or modulate protein kinases, in particular JNK protein kinases. These compounds and their pharmaceutically acceptable salts, and prodrugs of said compounds, are useful as anti-inflammatory agents, particularly useful in the treatment of rheumatoid arthritis. Also disclosed are pharmaceutical compositions containing such compounds, and methods for the treatment and/or control of inflammation, particularly in the treatment or control of rheumatoid arthritis, using these compounds.

    摘要翻译: 公开了具有下式的新的4,5-吡嗪氧吲哚:这些化合物抑制或调节蛋白激酶,特别是JNK蛋白激酶。 这些化合物及其药学上可接受的盐和所述化合物的前药可用作抗炎剂,特别可用于治疗类风湿性关节炎。 还公开了含有这些化合物的药物组合物,以及使用这些化合物治疗和/或控制炎症,特别是治疗或控制类风湿性关节炎的方法。

    1-thiaguanosine and process for preparing oxanosine and 1-thiaguanosine
    33.
    发明授权
    1-thiaguanosine and process for preparing oxanosine and 1-thiaguanosine 失效
    1-thiaguanosine和制备oxososine和1-thiaguanosine的方法

    公开(公告)号:US5243042A

    公开(公告)日:1993-09-07

    申请号:US561628

    申请日:1990-08-02

    IPC分类号: C07H19/24

    CPC分类号: C07H19/24

    摘要: The invention relates to antibacterially active 5-amino-3-(.beta.-D-ribofuranosyl)imidazo[4,5-d][1,3]thiazin-7(3H)-one, also referred to as 1-thiaguanosine, a composition and method comprising the same and processes and intermediates for the preparation of 1-thiaguanosine and 5-amino-3-(.beta.-D-ribofuranosyl)imidazo[4,5-d][1,3]oxazin-7(3H)-one, also referred to as oxanosine, a known compound.

    摘要翻译: 本发明涉及抗菌活性的5-氨基-3-(β-D-呋喃核糖基)咪唑并[4,5-d] [1,3]噻嗪-7(3H) - 酮,也称为1-噻二胍,a 包括其组成和方法,以及用于制备1-硫杂鸟嘌呤和5-氨基-3-(β-D-呋喃核糖基)咪唑并[4,5-d] [1,3]恶嗪-7(3H) - 酮的方法和中间体。 - 一种,也称为二恶烷,已知化合物。

    1,6- AND 1,8-NAPHTHYRIDINES
    34.
    发明申请
    1,6- AND 1,8-NAPHTHYRIDINES 审中-公开
    1,6-和1,8-萘啶

    公开(公告)号:US20120184562A1

    公开(公告)日:2012-07-19

    申请号:US13348668

    申请日:2012-01-12

    申请人: Kin-Chun Luk

    发明人: Kin-Chun Luk

    CPC分类号: C07D471/04

    摘要: Compounds of formula and pharmaceutically acceptable salts thereof are described, as well as the pharmaceutical compositions containing said compounds and their pharmaceutically acceptable salts, and the use of said compounds and pharmaceutical compositions for the treatment, control or amelioration of proliferative diseases, including cancer, Down syndrome or early onset Alzheimer's disease.

    摘要翻译: 本发明描述了式及其药学上可接受的盐的化合物,以及含有所述化合物及其药学上可接受的盐的药物组合物,以及所述化合物和药物组合物用于治疗,控制或改善增殖性疾病(包括癌症)Down 综合征或早发性阿尔茨海默氏病。

    Diazinopyrimidines
    38.
    发明申请
    Diazinopyrimidines 审中-公开
    二嗪嘧啶

    公开(公告)号:US20050261284A1

    公开(公告)日:2005-11-24

    申请号:US11190292

    申请日:2005-07-27

    CPC分类号: C07D498/04

    摘要: Compounds of formula I are p38 inhibitors: or a pharmaceutically acceptable salt thereof, wherein R1 is hydrogen or alkyl; R2 is alkyl, haloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, cycloalkyl, cycloalkylalkyl, heteroalkylsubstituted cycloalkyl, heterosubstituted cycloalkyl, heteroalkyl, cyanoalkyl, heterocyclyl, heterocyclylalkyl, or —Y1—C(O)—Y2—R11 (where Y1 and Y2 are independently either absent or an alkylene group and R11 is hydrogen, alkyl, haloalkyl, hydroxy, alkoxy, amino, monoalkylamino or dialkylamino); R3 is hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, heterosubstituted cycloalkyl, heterocyclyl, aryl, aralkyl, haloalkyl, heteroalkyl, cyanoalkyl, -alkylene-C(═O)—R4 (where R4 is hydrogen, alkyl, hydroxy, alkoxy, amino, monoalkylamino or dialkylamino), or acyl; Ar1 is aryl; X1 is O, NR5 or S, where R5 is hydrogen or alkyl; and X2 is a bond, O, NR6, S or CH2, where R6 is hydrogen or alkyl.

    摘要翻译: 式I化合物是p38抑制剂:或其药学上可接受的盐,其中R 1是氢或烷基; R 2是烷基,卤代烷基,芳基,芳烷基,杂芳基,杂芳烷基,环烷基,环烷基烷基,杂烷基取代的环烷基,杂取代的环烷基,杂烷基,氰基烷基,杂环基,杂环基烷基或-Y 1 > -C(O)-Y 2 -R 11(其中Y 1和Y 2)独立地为 不存在或亚烷基,R 11是氢,烷基,卤代烷基,羟基,烷氧基,氨基,单烷基氨基或二烷基氨基)。 R 3是氢,烷基,环烷基,环烷基烷基,杂取代的环烷基,杂环基,芳基,芳烷基,卤代烷基,杂烷基,氰基烷基, - 亚烷基-C(-O)-R 4 (其中R 4是氢,烷基,羟基,烷氧基,氨基,单烷基氨基或二烷基氨基)或酰基; Ar 1是芳基; X 1是O,NR 5或S,其中R 5是氢或烷基; 且X 2是O,NR 6,S或CH 2 2的键,其中R 6是氢 或烷基。

    Pyrazolo pyrimidines
    39.
    发明授权
    Pyrazolo pyrimidines 失效
    吡唑并嘧啶

    公开(公告)号:US08362023B2

    公开(公告)日:2013-01-29

    申请号:US13347718

    申请日:2012-01-11

    CPC分类号: C07D487/04

    摘要: Compounds of formula and pharmaceutically acceptable salts thereof are described, as well as the pharmaceutical compositions containing said compounds and their pharmaceutically acceptable salts, and the use of the compounds and pharmaceutical compositions for the treatment, control or amelioration of proliferative diseases, including cancer, Down syndrome or early onset Alzheimer's disease.

    摘要翻译: 本发明描述了式及其药学上可接受的盐的化合物,以及含有所述化合物及其药学上可接受的盐的药物组合物,以及该化合物和药物组合物用于治疗,控制或改善增殖性疾病(包括癌症)Down 综合征或早发性阿尔茨海默氏病。

    Phenalene derivatives
    40.
    发明授权
    Phenalene derivatives 失效
    萘衍生物

    公开(公告)号:US07217717B2

    公开(公告)日:2007-05-15

    申请号:US10852735

    申请日:2004-05-24

    CPC分类号: C07D471/06 C07D487/06

    摘要: Novel 1,3,4-triaza-phenalene and 1,3,4,6-tetraazaphenalene derivatives are disclosed. These compounds inhibit epidermal growth factor receptor (“EGFR”) tyrosine kinase. These compounds and their pharmaceutically acceptable salts and esters have antiproliferative activity and are useful, inter alia, in the treatment or control of cancer, in particular solid tumors. This invention also relates to pharmaceutical compositions containing such compounds and to methods of treating or controlling cancer, most particularly the treatment or control of breast, lung, colon and prostate tumors.

    摘要翻译: 公开了新的1,3,4-三氮杂 - 非那烯和1,3,4,6-四氮杂萘衍生物。 这些化合物抑制表皮生长因子受体(“EGFR”)酪氨酸激酶。 这些化合物及其药学上可接受的盐和酯具有抗增殖活性,尤其可用于治疗或控制癌症,特别是实体瘤。 本发明还涉及含有这些化合物的药物组合物以及治疗或控制癌症的方法,特别是乳腺癌,肺癌,结肠癌和前列腺肿瘤的治疗或控制。